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Background: Gonadotropin-releasing hormone agonists (GnRHa) are a safe and
effective treatment for precocious puberty. Triptorelin is one of the long lasting GnRHa,
which reversibly suppresses the pituitary-gonadal axis. Triptorelin-induced hypertension
(HTN) has rarely been reported in the literature.
Clinical Case/Methods: We report a 10-year-old girl with central precocious puberty
who, during treatment with triptorelin, developed an asymptomatic stage II HTN. Initial
workup showed no renal, thyroid, or electrolytes abnormalities. The renal ultrasound
showed no parenchymal disease and no increased renal resistance index suggestive
of a renal artery stenosis. Echocardiography and ocular fundoscopy were normal.
HTN (stage II) was confirmed with ambulatory blood pressure monitoring (ABPM). After
extensive literature review, we found 3 other cases of HTN secondary to GnRHa,
improving with endocrine treatment cessation. Therefore, antihypertensive treatment was
not started immediately in our patient. Indeed, after completion of her treatment with
triptorelin, we observed a complete normalization of her blood pressure (confirmed with
ABPM) without any medication.
Conclusion: Concomitantly to GnRHa treatment, our patient developed HTN, which
completely subsided after stopping triptorelin. The complete normalization of her blood
pressure, together with a negative workup for HTN strongly speaks for a causal effect of
her endocrine treatment. In this setting, estrogen depletion might play a role, although
this remains debated.
Keywords: arterial hypertension, central precocious puberty, Gonadotrophin releasing hormone agonist,
triptorelin, child—age
INTRODUCTION
The incidence of central precocious puberty (CPP) in children is ∼1/5,000–1/10,000 with a
female to male ratio of 20:1 (1). Gonadotropin-releasing hormone agonists (GnRHa) are the
treatment of choice for CPP. GnRHa administration results in an initial stimulation of pituitary
gonadotropin secretion followed by a complete and reversible suppression of the pituitary-gonadal
axis. Triptorelin, a long-lasting GnRHa, decreases testosterone levels in boys and estrogen levels in
girls. Triptorelin is a widely used drug with few reported adverse effects, such as erythema, bruising,
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pain, sterile abscesses, menopausal-like symptoms, and
anaphylaxis (2, 3). So far secondary arterial hypertension
(HTN) has been reported in only 3 patients with CPP (4–6).
We here report a new case of a 10-year-old girl with CPP
who developed a stage II HTN during triptorelin treatment,
followed by a complete normalization of her blood pressure
after triptorelin discontinuation, without any pharmacological
anti-hypertensive treatment.
CASE REPORT
An otherwise healthy 10-year-old girl was referred to the
pediatric nephrology unit for further investigation and treatment
of an asymptomatic stage II HTN (defined as ≥95th percentile
+ 12mm Hg). The girl was born at term, after an uneventful
pregnancy (birth weight 3,650 g). There were no reported post-
natal complications. Family history was remarkable for treated
HTN in her father since the age of 35 years. At the age of 7 years,
our patient was referred to a pediatric endocrinologist for further
investigation of bilateral breast development and pubic hair
growth, which started 6 months earlier. On clinical examination,
weight was 34 kg (+4.61 Standard Deviation Score, SDS), height
140 cm (+4.42 SDS), body mass index 17.35 kg/m2 (+1.44 SDS)
and the latest annual growth was 12.6 cm/year (+7.77 SDS).
Blood pressure was 99/66 mmHg (<90th percentile). She had
a Tanner stage 3 breast development, a Tanner stage 3 pubic
hair and a moderate axillary hair. Bone age (Greulich-Pyle) was
already advanced at first visit (8 years for a chronological age
of 7). Pelvic echography displayed an enlarged uterus for age
(uterine volume of 5.5ml). The right ovary was also enlarged
for age (2.6ml) with some follicles. The left ovary could not
be seen due to overlying bowel gas. The magnetic resonance
imaging of hypothalamus-pituitary axis (performed after the
Luteinizing Hormone Releasing Hormone (LHRH) stimulation
test) was normal. Estradiol level at first visit was 19 pmol/l.
Central isosexual precocious puberty was confirmed with a
positive LHRH stimulation test: LH peak 17.6 mU/l and Follicle
StimulationHormone (FSH) peak 11.8mU/l. To protect the child
from a distress of the dissociation induced by a mature (pubertal)
body in a psychologically and emotionally immature person,
encompassing obvious differences in school and among peers,
decision was taken to treat her. The patient received 3.75mg
(one set) at the onset of therapy. A second set was injected 14
days later, following strictly the recommendations provided by
the manufacturer (Ferring). No allergic reaction was observed.
However, an increased blood pressure was noticed after 2 months
treatment (121/80mm Hg). Blood pressure remained elevated
throughout the period of treatment leading to stop it at 9.5 years,
whereas the goal was to continue until 10 years.
She was then referred to the nephrology clinic for an
asymptomatic high blood pressure (139/85 mmHg), confirmed
with an ambulatory blood pressure monitoring (ABPM). Mean
day BP was 140/96 mmHg, mean night BP was 121/76 mmHg,
and systolic blood pressure load was 62.5%. Clinical exam was
normal and the initial workup showed no renal, thyroid, or
electrolytes abnormalities. There was no proteinuria. The renal
ultrasound showed no parenchymal disease and no increased
renal resistance index suggestive of a renal artery stenosis.
Echocardiography and fundoscopy were normal. After reading
the above-mentioned case reports, we purposely postponed
any antihypertensive treatment, hoping for a spontaneous
normalization of her blood pressure. Indeed, 6 weeks after
stopping GnRHa treatment, the girl had a normal office BP, and
a normal ABPM with a mean day and night BP values of 115/76
and 108/70 mmHg, respectively.
DISCUSSION
GnRHa represent the treatment of choice in children with CPP.
HTN occurrence during treatment has rarely been reported.
So far, only three cases of children with CPP and secondary
HTN during treatment with GnRHa have been published.
Calcaterra et al. (4) recently described a 7-year-old girl with
Triptorelin-treated CPP, who developed reversible HTN with
secondary concentric left ventricular hypertrophy, requiring
transient antihypertensive therapy. The authors suggested a
causal relationship between GnRHa treatment and HTN (4).
Siomou et al. (5) also described a case of a 10-year-old girl
with a Williams-Beuren syndrome and CPP who developed
HTN with Triptorelin treatment. In that case, blood pressure
totally normalized, without any anti-hypertensive medication
once GnRHa was discontinued (5), similar to our case. In both
cases, re-exposition to the offending drug was not performed.
Finally, Palma et al. also very recently report a girl with CPP
and arterial HTN during treatment with Triptorelin, HTN that
subsided once Triptorelin was interrupted (6).
Arterial HTN has been observed in other clinical settings
as well. Klink et al. report three adolescent girls with gender
dysphoria during treatment with the GnRHa Triptorelin (7). Re-
exposure to the offending drug in on patient strongly points
toward a causal relationship between Triptorelin and HTN. Also,
in adult patients, especially men with prostate cancer, GnRHa
has been associated with changes in body composition, obesity,
insulin resistance, and hypertension (8). Themechanisms leading
to arterial HTN are still unclear. Several authors have investigated
the pathophysiological mechanisms that underlie the occurrence
of HTN due to GnRHa therapy in animal models. Acs et al.
(9) showed in a rat model that triptorelin treatment decreases
estradiol levels and the passive diameter of the saphenous artery,
which were completely restored after estrogen replacement
therapy. These results suggest that the background mechanisms
for the increased incidence of HTN during GnRHa treatment
might be secondary to estrogen depletion (9). Várbíró et al.
(10) in a model of Triptorelin-ovariectomised rats, report
significant biomechanical changes, and alteration in the venous
distensibility. These abnormalities were completely reversed
with estradiol and medroxyprogesterone acetate hormone
replacement (10). Although estrogen depletion may play a
role in the pathogenesis of Triptorelin-induced HTN, this
should be further investigated. Finally, whereas the blood
pressure of a growing child is usually matched to normal
values for age and sex, it should rather be matched to
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height or weight age as one of the hallmark of central
precocious puberty is to induce a high growth velocity and
therefore relatively tall stature with increased weight gain. In an
observational study (11), blood pressure of children with CPP
was significantly increased but generally appropriate for height
age or weight age.
In our case report, the presence of a normal BP before
initiation of Triptorelin and the complete normalization of the
blood pressure after stopping it, points toward a causal effect of
the GnRHa treatment. Given the sequence of pharmacological
interventions and the current literature data, we speculate
that the HTN was secondary to GnRHa treatment. We felt
it unnecessary and unethical to re-challenge the patient with
Triptorelin. On the basis of our case, 3 previously reported cases
and other supporting literature data, we recommend monitoring
the blood pressure in every child receiving GnRHa treatment, and
in particular Triptorelin.
We obtained parental consent from the parents of the patient
for the publication of this case report.
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